


nature
REVIEWS


www.nature.com/reviews

CANCER
CLINICAL ONCOLOGY




Produced with support from:





The *Nature Reviews Cancer* calendar for 2014 has a clinical twist. As well as plundering our own image bank for more clinically oriented figures, we have chosen six images and figures from our sister journal, *Nature Reviews Clinical Oncology*. All of these images convey some of the important aspects of clinical cancer research, thus producing a ‘bench to bedside and back again’ overview. At the end of the calendar we have included some additional Reviews and Perspectives that discuss important topics that are related to each figure, such as biomarkers, targeted therapies, cancer imaging, detection and diagnosis. We have also included images that focus on particular types of cancer, such as ovarian, lung and prostate. As always, we are indebted to our authors for producing such good ideas for figures and the excellent articles that go with them.

We hope that you find this calendar of use and we look forward to meeting some of you at the 2014 cancer-related conferences that are listed in the back of the calendar. Our calendar is freely available thanks to support from OriGene.



Nature Reviews Cancer:

<http://www.nature.com/nrc/index.html>

Nature Reviews Clinical Oncology:

<http://www.nature.com/nrclinonc/index.html>

Follow @NatureRevCancer and @NatRevClinOncol on Twitter: <http://twitter.com/NatureRevCancer>

<http://twitter.com/NatRevClinOncol>

Calendar compiled and edited by Nicola McCarthy and Lisa Hutchinson

Copy-edited by Simon Neil

Designed and illustrated by Lara Crow

LIST OF ABBREVIATIONS USED IN THE CALENDAR:

CAIX, carbonic anhydrase 9; COX-2, cyclooxygenase 2; CRC, colorectal cancer; ctDNA, circulating tumour DNA; CXCR, CXC-chemokine receptor; ECM, extracellular matrix; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; FGF, fibroblast growth factor; FGFR, FGF receptor; FOXO3A, forkhead box O3A; FVIIa, factor VIIa; GPVI, glycoprotein 6; GPIIb, glycoprotein inhibitor b α ; HDAC, histone deacetylase; HGF, hepatocyte growth factor; HGPIN, high-grade prostatic intraepithelial neoplasia; HIF-1, hypoxia-inducible factor 1; ICAM, intercellular adhesion molecule;

IL, interleukin; mTOR, mammalian target of rapamycin; NF- κ B, nuclear factor- κ B; PAR, prostate apoptosis response; PDGF, platelet-derived growth factor; PDGFR, PDGF receptor; PGE2, prostaglandin E2; PPAR γ , peroxisomal proliferator-activated receptor- γ ; PSGL1, P selectin ligand 1; SDF1 α , stromal cell-derived factor 1 α ; sLe, sialyl Lewis antigen; TCF, transcription factor 1 α ; TGF α , transforming growth factor- α ; TSC, tuberous sclerosis; VCAM, vascular cellular adhesion molecule; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; VHL, Von Hippel-Lindau; VWF, Von Willebrand factor.




Streamline your gene-related research with OriGene's broad gene centric tools for molecular and cellular research. Our product offering includes:

- 30,000 validated antibodies
- 200,000 expression cDNA clones, with or without tags
- 200,000 RNAi reagents (shRNA, siRNA and miRNA)
- 10,000 purified human proteins from human cells
- 140,000 human tissues for cancer research
- Constructing any plasmid vectors via gene synthesis

Type the name of your favorite gene into OriGene's search box and be amazed.

Join thousands of scientists who experienced the quality and convenience of OriGene's tools. Put your project into power drive! (www.origene.com)



Red blood cell

Circulating tumour cell

Phagocyte

Mutation

Chromosome

Healthy cell

Healthy tissue

Apoptosis or necrosis

Tumour cell


Apoptosis

Blood plasma or serum sample containing ctDNA



Endothelial cell

Inflamed tissue


SUNDAY	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31	




SUNDAY	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	




SUNDAY	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31					
www.origene.com						



SUNDAY	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30			



SUNDAY	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31




nature
REVIEWS


CANCER

JUNE 2014

SUNDAY	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30					




SUNDAY	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31		




Tumour cell


Cohesion



Coagulation




Adhesion




● Thrombin	● VWF	🌿 PSGL1
👉 Integrin $\alpha\text{IIb}\beta\text{3}$	👉 CD44	👉 L-selectin
👉 Integrin $\alpha\text{v}\beta\text{3}$	🌿 GPIV	👉 E-selectin
👉 Integrin $\alpha\text{M}\beta\text{2}$	🌿 Fibrinogen	👉 P-selectin
👉 PAR4	👉 GPIba	👉 Mucins
👉 PAR1 and PAR2	👉 Wiebel-Palade bodies	
👉 sLe ^x and sLe ^a	👉 ICAM and VCAM	


SUNDAY	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31						




SUNDAY	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30				



SUNDAY	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31	



SUNDAY	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30						



SUNDAY	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30	31			


JANUARY

BIOMARKERS

Adapted from Crowley, E. et al. Liquid biopsy: monitoring cancer-genetics in the blood. *Nature Rev. Clin. Oncol.* **10**, 472–484 (2013)

FURTHER READING

- Schwarzenbach, H., Hoon, D. S. B. & Pantel, K. Cell-free nucleic acids as biomarkers in cancer patients. *Nature Rev. Cancer* **11**, 426–437 (2011)
- De Mattos-Arruda, L., et al. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. *Nature Rev. Clin. Oncol.* **10**, 377–389 (2013)
- Hanash, S. M., Baik, C. S. & Kallioniemi, O. Emerging molecular biomarkers — blood-based strategies to detect and monitor cancer. *Nature Rev. Clin. Oncol.* **8**, 142–150 (2011)




MARCH

COLON CANCER

Adapted from Chia, W. K., Ali, R. & Toh, H. C. Aspirin as adjuvant therapy for colorectal cancer — reinterpreting paradigms. *Nature Rev. Clin. Oncol.* **9**, 561–570 (2012)

FURTHER READING

- Langley, R. E. & Rothwell, P. M. Biological markers: Potential biomarker for aspirin use in colorectal cancer therapy. *Nature Rev. Clin. Oncol.* **10**, 8–10 (2013)
- Thun, M. J., Jacobs, E. J. & Patrono, C. The role of aspirin in cancer prevention. *Nature Rev. Clin. Oncol.* **9**, 259–267 (2012)
- Wang, D. & DuBois, R. N. Eicosanoids and cancer. *Nature Rev. Cancer* **10**, 181–193 (2010)




MAY

CELL CYCLE

Adapted from the 2011 cover of *Nature Rev. Clin. Oncol.* The image shows human cancer cell lines (HeLa) with α -tubulin pseudo-coloured red, DNA in blue and the midbody pseudo-coloured green.

FURTHER READING

- Alcolea, M. P. & Jones, P. H. Tracking cells in their native habitat: lineage tracing in epithelial neoplasia. *Nature Rev. Cancer* **13**, 161–171 (2013)
- Sadasivam, S. & DeCaprio, J. A. The DREAM complex: master coordinator of cell cycle-dependent gene expression. *Nature Rev. Cancer* **13**, 585–595 (2013)
- Komlodi-Pasztor, E., Sackett, D., Wilkerson, J. & Fojo, T. Mitosis is not a key target of microtubule agents in patient tumors. *Nature Rev. Clin. Oncol.* **8**, 244–250 (2011)




FEBRUARY

CANCER IMAGING

Adapted from Vakoc, B. J., Fukumura, D., Jain, R. K. & Bouma, B. E. Cancer imaging by optical coherence tomography: preclinical progress and clinical potential. *Nature Rev. Cancer* **12**, 363–368 (2012). Image is reproduced, with permission, from Vakoc, B. J. et al. *Nature Med.* **15**, 1219–1223 (2009) © (2009) Macmillan Publishers Ltd. All rights reserved.

FURTHER READING

- Nguyen, Q. T. & Tsien, R. Y. Fluorescence-guided surgery with live molecular navigation — a new cutting edge. *Nature Rev. Cancer* **13**, 653–662 (2013)
- Morgan, B. Opportunities and pitfalls of cancer imaging in clinical trials. *Nature Rev. Clin. Oncol.* **8**, 517–527 (2011)
- Focus on Imaging www.nature.com/nrclinonc/focus/imaging




APRIL

PROSTATE CANCER

Adapted from Kumar-Sinha, C., Tomlins, S. A. & Chinnaiyan, A. M. Recurrent gene fusions in prostate cancer. *Nature Rev. Cancer* **8**, 497–511 (2008)

FURTHER READING

- Sutcliffe, S. & Colditz, G. A. Prostate cancer: is it time to expand the research focus to early-life exposures? *Nature Rev. Cancer* **13**, 208–218 (2013)
- Risbridger, G. P., Davis, I. D., Birrell, S. N. & Tilley, W. D. Breast and prostate cancer: more similar than different. *Nature Rev. Cancer* **10**, 205–212 (2010)
- Scher, H. I., Morris, M. J., Larson, S. & Heller, G. Validation and clinical utility of prostate cancer biomarkers. *Nature Rev. Clin. Oncol.* **10**, 225–234 (2013)




JUNE

DIAGNOSIS

Adapted from Espina, V. & Liotta, L. A. What is the malignant nature of human ductal carcinoma *in situ*? *Nature Rev. Cancer* **11**, 68–75 (2011)

FURTHER READING


- Hamilton, W. Diagnosis: Cancer diagnosis in UK primary care. *Nature Rev. Clin. Oncol.* **9**, 251–252 (2012)
- Lao-Sirieix, P. & Fitzgerald, R. C. Screening for oesophageal cancer. *Nature Rev. Clin. Oncol.* **9**, 278–287 (2012)
- Kulasingam, V., Pavlou, M. P. & Diamandis, E. P. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. *Nature Rev. Cancer* **10**, 371–378 (2010)



JULY

BRAIN CANCER

Adapted from the 2012 cover of *Nature Rev. Clin. Oncol.* An immunofluorescence image of primary culture differentiated human glioma stem cells derived from adult glioblastoma. Cells have pleomorphic nuclei and lack of contact inhibition.



FURTHER READING

- Tanaka, S., Louis, D. N., Curry, W. T., Batchelor, T. T. & Dietrich, J. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? *Nature Rev. Clin. Oncol.* **10**, 14–26 (2013)
- Steeg, P. S., Camphausen, K. A. & Smith, Q. R. Brain metastases as preventive and therapeutic targets. *Nature Rev. Cancer* **11**, 352–363 (2011)
- Huse, J. T. & Holland, E. C. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. *Nature Rev. Cancer* **10**, 319–331 (2010)


SEPTEMBER

KIDNEY CANCER

Adapted from Bellmunt, J., Teh, B. T., Tortora, G. & Rosenberg, J. E. Molecular targets on the horizon for kidney and urothelial cancer. *Nature Rev. Clin. Oncol.* **10**, 557–570 (2013)

FURTHER READING


- Escudier, B., Szczylik, C., Porta, C. & Gore, M. Treatment selection in metastatic renal cell carcinoma: expert consensus. *Nature Rev. Clin. Oncol.* **9**, 327–337 (2012)
- Huff, V. Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene. *Nature Rev. Cancer* **11**, 111–121 (2011)
- Biswas, S. & Eisen, T. Immunotherapeutic strategies in kidney cancer — when TKIs are not enough. *Nature Rev. Clin. Oncol.* **6**, 478–487 (2009)



NOVEMBER

DRUG RESPONSE

Adapted from the 2013 cover of *Nature Rev. Clin. Oncol.* Immunofluorescence staining for β -catenin and FOXO3A proteins as potential markers for the prediction of drug response in a histological section of a human colon carcinoma.



FURTHER READING

- Kuczyński, E. A., Sargent, D. J., Grothey, A. & Kerbel, R. S. Drug rechallenge and treatment beyond progression — implications for drug resistance. *Nature Rev. Clin. Oncol.* <http://dx.doi.org/10.1038/nrclinonc.2013.158> (2013)
- La Thangue, N. B. & Kerr, D. J. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. *Nature Rev. Clin. Oncol.* **8**, 587–596 (2011)


AUGUST

METASTASIS

Adapted from Gay, L. J. & Felding-Habermann, B. Contribution of platelets to tumour metastasis. *Nature Rev. Cancer* **11**, 123–134 (2011)

FURTHER READING

- De Craene, B. & Bex, G. Regulatory networks defining EMT during cancer initiation and progression. *Nature Rev. Cancer* **13**, 97–110 (2013)
- Brabletz, T. To differentiate or not — routes towards metastasis. *Nature Rev. Cancer* **12**, 425–436 (2012)
- Mina, L. A. & Sledge, G. W. Jr. Rethinking the metastatic cascade as a therapeutic target. *Nature Rev. Clin. Oncol.* **8**, 325–332 (2011)
- Focus on Migration and metastasis www.nature.com/nrc/focus/migration




OCTOBER

OVARIAN CANCER

Adapted from Vaughan, S. et al. Rethinking ovarian cancer: recommendations for improving outcomes. *Nature Rev. Cancer* **11**, 719–725 (2011)

FURTHER READING

- Johnson, P. A. & Giles, J. R. The hen as a model of ovarian cancer. *Nature Rev. Cancer* **13**, 432–436 (2013)
- Kippes, E., Tan, D. S. P. & Kaye, S. B. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. *Nature Rev. Cancer* **13**, 273–282 (2013)
- Coleman, R. L., Monk, B. J., Sood, A. K. & Herzog, T. J. Latest research and treatment of advanced-stage epithelial ovarian cancer. *Nature Rev. Clin. Oncol.* **10**, 211–224 (2013)




DECEMBER

LUNG CANCER

Adapted from Sun, S., Schiller, J. H. & Gazdar, A. F. Lung cancer in never smokers — a different disease. *Nature Rev. Cancer* **7**, 778–790 (2007)

FURTHER READING

- Houghton, A. M. Mechanistic links between COPD and lung cancer. *Nature Rev. Cancer* **13**, 233–245 (2013)
- Pao, W. & Chmielecki, J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. *Nature Rev. Cancer* **10**, 760–774 (2010)
- Mok, T. S. Personalized medicine in lung cancer: what we need to know. *Nature Rev. Clin. Oncol.* **8**, 661–668 (2011)



CALENDAR OF EVENTS

2014

	Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
JANUARY				1	2	3	4
	5	6	7	8	9	10	11
	12	13	14	15	16	17	18 AACR-Prostate
	19 cancer foundation conference, California, USA			22	23	24	25
	26	27	28	29 AACR: Cancer susceptibility and susceptibility syndromes, California, USA			
FEBRUARY							1
	2 Keystone: Developmental pathways in cancer; and Stem cells and cancer, Banff, Canada				6	7	8
	9	10	11	12	13 26 th Lorne cancer conference, Victoria, Australia		
	16	17	18	19	20	21	22
	23	24	25	26	27	28	
MARCH							1
	2	3	4	5	6	7	8
	9 Keystone: Immune evolution in cancer, Whistler, Canada			12	13	14	15
	16 Keystone: Tumor metabolism, Whistler, Canada			19	20	21	22
	23	24 30 th Genes and cancer meeting, Cambridge, UK			27	28	29
30	31						
APRIL			1	2	3	4	5 AACR Annual
	6 Meeting, California, USA		8	9	10	11	12
	13	14	15	16	17	18	19
	20	21	22	23	24	25	26
	27	28	29	30			
MAY					1	2	3
	4	5	6	7	8 IMPAKT 2014 Breast cancer conference, Brussels, Belgium		
	11	12	13	14	15	16	17
	18	19	20	21	22	23 EMBO conference: Cellular signalling	
	25 and cancer therapy, Cavtat, Croatia		27	28	29	30 50 th ASCO Annual Meeting, Illinois, USA	
JUNE	1	2	3	4 GRC: Cell polarity signaling, Massachusetts, USA			7
	8	9	10	11	12	13	14
	15	16	17	18	19	20	21
	22	23	24	25	26	27	28
	29	30					

	Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
JULY			1	2	3	4	5 23 rd Biennial
	6 Congress of the EACR, Munich, Germany		8	9	10	11	12
	13	14	15	16	17	18	19
	20	21	22	23	24	25	26
	27	28	29	30	31		
AUGUST						1	2
	3 GRC: Rare cells in circulation, Massachusetts, USA			6	7	8	9
	10	11	12	13	14	15	16
	17	18	19	20	21	22	23
	24	25	26	27	28	29	30
	31						
SEPTEMBER		1	2	3	4	5	6
	7	8	9	10	11	12	13
	14	15	16	17	18	19	20
	21	22	23	24	25	26 ESMO 2014 Congress, Madrid, Spain	
	28	29	30				
OCTOBER				1	2	3	4
	5	6	7	8	9	10	11
	12	13	14	15	16	17	18
	19	20	21	22	23	24	25
	26 AACR: Translational Cancer Research for Basic Scientists Workshop, Massachusetts, USA					31	
NOVEMBER							1
	2	3	4	5	6	7	8
	9	10	11	12	13	14	15
	16	17	18 EORTC–AACR–NCI International symposium, Barcelona, Spain	21	22		
	23	24	25	26	27	28	29
	30						
DECEMBER		1	2	3 World Cancer Congress, Melbourne, Australia			6
	7	8	9 San Antonio Breast Cancer Symposium, Texas, USA		12	13	
	14	15	16	17	18	19	20
	21	22	23	24	25	26	27
	28	29	30	31			



nature publishing group

4 Crinan Street,
London, N1 9XW
www.nature.com/nrc
www.nature.com/nrclinonc